# A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

> **NCT05101356** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianhong Li** · enrollment: 77 (estimated)

## Conditions studied

- Advanced Adenocarcinoma
- Advanced Malignant Solid Neoplasm
- Metastatic Adenocarcinoma
- Metastatic Malignant Solid Neoplasm
- Recurrent Adenocarcinoma
- Recurrent Malignant Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Antineoplastic Vaccine
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05101356
- **Lead sponsor:** Tianhong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-13
- **Primary completion:** 2026-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101356, "A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05101356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*